Director, Drug Development AI Nexus Decision Integration Lead is a newly created leadership role at the intersection of drug development, artificial intelligence, and operating model transformation. This individual will serve as the primary bridge between Drug Development, Research and the AI Nexus team, translating strategic priorities, business requirements, and decision-making needs into AI-enabled workflows, governance processes, data requirements, and platform capabilities that improve the quality, speed, and consistency of development decisions.
Positioned within Drug Development Excellence (DDE), this role has broad cross-functional reach across Drug Development and plays a critical role in advancing BMS's vision for AI-enabled decision-making. The scope extends beyond the integration of AI Nexus into Global Program Teams (GPTs) to encompass portfolio-level decision workflows, governance cadences, and the broader agentic intelligence ecosystem being established across R&D. Working in close partnership with BI&T, Research, and functional leaders, the role will drive strategic prioritization, workflow redesign, AI-data readiness, adoption, and organizational change to enable new ways of working.
The ideal candidate is a credible drug development leader who can bridge the worlds of science, operations, and technology. They possess a deep understanding of how development decisions are made and can translate complex business needs into scalable, AI-enabled solutions by partnering effectively with business, data, and technology teams. They are equally comfortable discussing portfolio strategy, development planning, phase transitions, governance processes, data architecture, and emerging AI capabilities, and they can connect these domains to deliver measurable business impact. Success in this role requires strategic thinking, creativity, influence without authority, and the ability to inspire and mobilize cross-functional teams toward AI-native ways of working.
AI Nexus Integration & Embedded Workflow Redesign- Translate Drug Development strategic priorities, business requirements, and decision-making needs into scalable business capabilities, AI-enabled workflows, data requirements, and AI Nexus roadmap priorities.
- Serve as the Drug Development anchor for the AI Nexus platform, translating the AI Nexus vision into executable workflows embedded directly in Global Program Teams (GPTs) and governance forums
- Map, prioritize, and redesign key Drug Development decision points - from Phase transition and regulatory milestone reviews to portfolio-level governance - to leverage AI Nexus-enabled evidence, agentic analysis, and learning loops
- Partner with AI Nexus Product Leadership (BI&T) and Platform Engineering teams to communicate Drug Development decision needs and ensure the platform is built and iterated to serve them
- Operate as an "embedded translator" between Drug Development operational and clinical needs and AI Nexus technical capabilities - converting ambiguous decision problems into structured, AI-ready workflow requirements with defined data requirements
Change Leadership & Adoption- Drive AI Nexus adoption across Drug Development through demonstrated value in live GPTs and culture-driven change management - not through mandates or training-first approaches
- Build and sustain a network of Drug Development champions, GPT leads, and functional stakeholders who actively use and shape Nexus workflows
- Develop and execute adoption strategies tailored to Drug Development archetypes - study teams, clinicians, program leaders, and executive leaders - recognizing that each group engages with agentic systems and data differently
- Serve as a visible change agent for the broader evolution of Drug Development toward an agentic operating model, demonstrating what AI-augmented ways of working look like in practice
- Actively contribute to the AI Nexus SteerCo and cross-functional working groups, ensuring Drug Development priorities are reflected in platform roadmap and investment decisions
Operating Model & Continuous Improvement- Help define and operationalize an AI-native Drug Development operating model, embedding AI-enabled decision support, governance integration, learning systems, and workflow standards across development processes.
- Design scalable frameworks that can extend from GPT-level integration to broader Drug Development governance and cross-TA portfolio processes
- Track and report on AI Nexus adoption, impact, and return across Drug Development functions; ensure metrics align to decision quality, speed and portfolio outcomes, and use data to drive prioritization and course correction
- Contribute to the broader DD vision of operational excellence - where quality, speed, and efficiency are produced as outcomes of an integrated, intelligence-driven system
We hire for skills and capabilities, not just credentials - if this role excites you, but doesn't perfectly match your resume, we encourage you to apply anyway.
Compensation Overview:Brisbane - CA - US: $251,570 - $304,839Cambridge Crossing: $251,570 - $304,839 Madison - Giralda - NJ - US: $224,610 - $272,178Princeton - NJ - US: $224,610 - $272,178
The starting pay range(s) listed above is for full-time employees (FTE). You may also be eligible for additional discretionary incentive cash and stock opportunities. We determine starting pay thoughtfully - carefully considering the nature of the role, required skills, work location, schedule and the knowledge and experience you bring. Final compensation is guided by pay equity principles and applicable employment laws. Compensation programs are reviewed on an ongoing basis and may be adjusted over time to reflect evolving market factors, and individual, team or Company performance.
Benefits:Subject to the terms and conditions of the applicable plans then in effect, you may be eligible to participate in our comprehensive benefit plans - including wellbeing support, retirement and financial protection benefits, and insurance offerings (medical, dental, vision, life and disability).
U.S.-based exempt employees are eligible for Flexible Time Off (FTO), which provides paid time off without a set accrual limit, subject to manager approval, along with 11 paid company holidays each year.
Non-exempt employees, RayzeBio employees, and employees located in Puerto Rico receive 160 hours of paid vacation annually for new hires (subject to manager approval), 11 paid company holidays, and 3 optional holidays.
Depending on eligibility, employees may also have access to additional time-off benefits, including paid sick leave, up to two paid volunteer days per year, summer hours flexibility, and leaves of absence for medical, personal, parental, caregiver, bereavement, or military needs. Eligible employees also enjoy an annual Global Shutdown between Christmas Day and New Year's Day.
U.S.-based job seekers can explore full benefit offerings at https://careers.bms.com/benefits
How We WorkWhere you work matters - because collaboration, innovation and patient impact happen in many settings. Our roles are structured across four work models: site-essential, site-by-design, field-based and remote-by-design. The model assigned to this role is based on its core responsibilities. Learn more at https://careers.bms.com/ways-of-working.
